

M. Sakanaka, et al.
U.S.S.N. 09/913,669
Page 5

REMARKS

The Applicants appreciate the Examiner's thorough examination of the subject application. Applicants request reconsideration of the subject application based on the following remarks.

Claims 32-50 are pending in the application. Claims 1-31 have been cancelled. Applicants expressly reserve the right to pursue the subject matter of the cancelled claims in this or a subsequent application. Support for new claims 32-50 can be found in the claims as originally filed and throughout the specification.

Claims 3, 4-13, 15-24, and 28-31 were rejected under 35 U.S.C. §112, second paragraph, as being allegedly indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 21-23 and 31 were rejected under 35 U.S.C. 101 for allegedly not being in proper process claim format.

Claims 1, 2, 4-13, 15-20, 24, and 28-30 were rejected under 35 U.S.C. §102(b) as being allegedly anticipated Lim (*Neuroscience Research*, 28, 191-200, 1997).

Although Applicants disagree with the arguments presented in connection with the above referenced rejections under §101, 102, and 112, in the interest of expediting prosecution, claims 1-31 have been cancelled by the instant response. Applicants expressly reserve the right to pursue the subject matter of these cancelled claims in this or a subsequent amendment.

New claims 32-50 are herein presented and are directed to methods of treatment of various diseases and injuries associated with damage or injury of a patient's nervous system tissues or spinal cord. Lim neither discloses nor suggests methods of treatment of


M. Sakanaka, et al.
U.S.S.N. 09/913,669
Page 6

diseases or injuries to the nervous system comprising the administration of a pharmaceutical composition comprising a therapeutic agent selected from ginsenoside Rb₁, its metabolites or salts thereof.

Although it is not believed that any additional fees are needed to consider this submission, the Examiner is hereby authorized to charge our deposit account no. 04-1105 should any fee be deemed necessary.

Respectfully submitted,

Date: October 31, 2003



John B. Alexander (Reg. No. 48,399)
EDWARDS & ANGELL, LLP
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
P. O. Box 9169
Boston, MA 02209
Tel: (617) 439-4444
Fax: (617) 439-4170 / 7748